Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia

British Journal of Pharmacology

Volumn 161, Issue 8, 2010, Pages 1708-1721

  Vikram, Ajit ^a   Jena, Gopabandhu ^a   Ramarao, Poduri ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Apoptosis; Diabetes; Free fatty acids; High fat diet; Hyperinsulinaemia; Insulin resistance; Lipid; Testosterone

Indexed keywords

CHOLESTEROL; CYCLINE; GLUCOSE; INSULIN; LIPID; MITOGEN ACTIVATED PROTEIN KINASE; PIOGLITAZONE; TESTOSTERONE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CASTRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HISTOPATHOLOGY; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID DIET; LIPID STORAGE; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; TESTOSTERONE BLOOD LEVEL;

ANIMALS; APOPTOSIS; CASTRATION; CELL PROLIFERATION; DIETARY FATS; DISEASE MODELS, ANIMAL; GLUCOSE TOLERANCE TEST; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; ORGAN SIZE; PPAR GAMMA; PROSTATE; PROSTATIC HYPERPLASIA; RATS; RATS, SPRAGUE-DAWLEY; TESTOSTERONE; THIAZOLIDINEDIONES;

EID: 78649430178     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00994.x     Document Type: Article

References (44)

1. Alexander S, Mathie A, Peters J (2009). Guide to receptors and channels (GRAC), 4th edition. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Alonso-Magdalena P, Brossner C, Reiner A, Cheng G, Sugiyama N, Warner M et al. (2009). A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc Natl Acad Sci USA 106: 2859-2863.
3. Attia N, Tamborlane WV, Heptulla R, Maggs D, Grozman A, Sherwin RS et al. (1998). The metabolic syndrome and insulin-like growth factor I regulation in adolescent obesity. J Clin Endocrinol Metab 83: 1467-1471.
4. Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984). The development of human benign prostatic hyperplasia with age. J Urol 132: 474-479.
5. Cai X, Haleem R, Oram S, Cyriac J, Jiang F, Grayhack JT et al. (2001). High fat diet increases the weight of rat ventral prostate. Prostate 49: 1-8.
6. Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Sesterhenn IA, Mostofi FK et al. (2002). Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate 52: 98-105.
7. Collino M, Aragno M, Castiglia S, Miglio G, Tomasinelli C, Boccuzzi G et al. (2010). Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. Br J Pharmacol 160: 1892-1902.
8. Escobar EL, Gomes-Marcondes MC, Carvalho HF (2009). Dietary fatty acid quality affects AR and PPARgamma levels and prostate growth. Prostate 69: 548-558.
9. Fan W, Yanase T, Morinaga H, Okabe T, Nomura M, Daitoku H et al. (2007). Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem 282: 7329-7338.
10. Hammarsten J, Hogstedt B (1999). Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 8: 29-36.
11. Hannah JS, Howard BV (1994). Dietary fats, insulin resistance, and diabetes. J Cardiovasc Risk 1: 31-37.
12. Imamov O, Morani A, Shim GJ, Omoto Y, Thulin-Andersson C, Warner M et al. (2004). Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. Proc Natl Acad Sci USA 101: 9375-9380.
13. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M et al. (1999). Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 104: 447-457.
14. Kasturi S, Russell S, McVary KT (2006). Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 7: 288-292.
15. Kirchhoff K, Kantartzis K, Machann J, Schick F, Thamer C, Machicao F et al. (2007). Impact of different fat depots on insulin sensitivity: predominant role of liver fat. J Diabetes Sci Technol 1: 753-759.
16. Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H et al. (2006). Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem 281: 8748-8755.
17. Lebovitz HE, Banerji MA (2001). Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 56: 265-294.
18. Lundgren M, Svensson M, Lindmark S, Renstrom F, Ruge T, Eriksson JW (2007). Fat cell enlargement is an independent marker of insulin resistance and 'hyperleptinaemia'. Diabetologia 50: 625-633.
19. Marker PC, Donjacour AA, Dahiya R, Cunha GR (2003). Hormonal, cellular, and molecular control of prostatic development. Dev Biol 253: 165-174.
20. Medina-Gomez G, Gray S, Vidal-Puig A (2007). Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgammacoactivator-1 (PGC1). Public Health Nutr 10: 1132-1137.
21. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H (2009). Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. Br J Pharmacol 157: 415-426.
22. Nam SY, Lee EJ, Kim KR, Cha BS, Song YD, Lim SK et al. (1997). Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord 21: 355-359.
23. Nandeesha H, Koner BC, Dorairajan LN, Sen SK (2006). Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 370: 89-93.
24. Natali A, Ferrannini E (2006). Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49: 434-441.
25. O'Neill E, Kolch W (2004). Conferring specificity on the ubiquitous Raf/MEK signalling pathway. Br J Cancer 90: 283-288.
26. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A (2007). The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 51: 199-203.
27. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L et al. (2006). Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 91: 2562-2568.
28. Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE (2008). Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol 153: 636-645.
29. Rahman NU, Phonsombat S, Bochinski D, Carrion RE, Nunes L, Lue TF (2007). An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat. BJU Int 100: 658-663.
30. Rasouli N, Raue U, Miles LM, Lu T, Di Gregorio GB, Elbein SC et al. (2005). Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab 288: E930-E934.
31. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS (2008). Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 9: 1087-1108.
32. Schinner S, Kratzner R, Baun D, Dickel C, Blume R, Oetjen E (2009). Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs. Br J Pharmacol 157: 736-745.
33. Shaul YD, Seger R (2007). The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta 1773: 1213-1226.
34. Srinivasan K, Patole PS, Kaul CL, Ramarao P (2004). Reversal of glucose intolerance by pioglitazone in high fat diet-fed rats. Methods Find Exp Clin Pharmacol 26: 327-333.
35. Sugimura Y, Cunha GR, Donjacour AA (1986). Morphogenesis of ductal networks in the mouse prostate. Biol Reprod 34: 961-971.
36. Takatori S, Zamami Y, Yabumae N, Hanafusa N, Mio M, Egawa T et al. (2008). Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemia. Br J Pharmacol 153: 1388-1398.
37. Torring N, Vinter-Jensen L, Pedersen SB, Sorensen FB, Flyvbjerg A, Nexo E (1997). Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate. J Urol 158: 222-227.
38. Vikram A, Tripathi DN, Ramarao P, Jena GB (2008). Intervention of d-glucose ameliorates the toxicity of streptozotocin in accessory sex organs of rat. Toxicol Appl Pharmacol 226: 84-93.
39. Vikram A, Jena GB, Ramarao P (2010a). Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate 70: 79-89.
40. Vikram A, Jena GB, Ramarao P (2010b). Insulin-resistance and benign prostatic hyperplasia: the connection. Eur J Pharmacol 641: 75-81.
41. Weickert MO, Pfeiffer AF (2006). Signalling mechanisms linking hepatic glucose and lipid metabolism. Diabetologia 49: 1732-1741.
42. Wu CT, Altuwaijri S, Ricke WA, Huang SP, Yeh S, Zhang C et al. (2007). Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci USA 104: 12679-12684.
43. Yang X, Smith U (2007). Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia 50: 1127-1139.
44. Ye JM, Dzamko N, Cleasby ME, Hegarty BD, Furler SM, Cooney GJ et al. (2004). Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia 47: 1306-1313.